Haleon (NYSE:HLN) Stock Rating Lowered by Jefferies Financial Group

Haleon (NYSE:HLN) was downgraded by analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued on Wednesday, Marketbeat.com reports.

A number of other brokerages also recently issued reports on HLN. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Friday, September 25th. Zacks Research lowered Haleon from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 22nd. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft raised Haleon from a “sell” rating to a “hold” rating in a research report on Friday, October 30th. Finally, Wall Street Zen lowered Haleon from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.90.

Haleon Trading Up 1.0%

HLN opened at $8.85 on Wednesday. The firm has a market cap of $38.95 billion, a P/E ratio of 22.68, a P/E/G ratio of 2.05 and a beta of 0.15. Haleon has a 12 month low of $8.38 and a 12 month high of $11.28. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. The stock has a 50-day moving average of $9.49 and a 200 day moving average of $9.76.

Institutional Trading of Haleon

Several institutional investors have recently added to or reduced their stakes in HLN. Brighton Jones LLC boosted its position in shares of Haleon by 7.0% during the third quarter. Brighton Jones LLC now owns 26,464 shares of the company’s stock valued at $238,000 after buying an additional 1,732 shares during the period. Ethic Inc. raised its holdings in shares of Haleon by 1.5% in the third quarter. Ethic Inc. now owns 111,428 shares of the company’s stock worth $1,003,000 after buying an additional 1,658 shares during the period. StoneX Group Inc. purchased a new stake in shares of Haleon in the third quarter worth approximately $129,000. May Hill Capital LLC lifted its stake in shares of Haleon by 20.2% during the 3rd quarter. May Hill Capital LLC now owns 22,564 shares of the company’s stock worth $203,000 after acquiring an additional 3,792 shares during the last quarter. Finally, CenterBook Partners LP bought a new stake in shares of Haleon during the 3rd quarter worth approximately $179,000. Institutional investors own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.